No effect of deleted in malignant brain tumors 1 deficiency on chemotherapy induced murine intestinal mucositis

Anders B. Nexoe1,2,8, Andreas A. Pedersen1,8, Sebastian von Huth1,3, Grith L. Sorensen1, Uffe Holmskov1, Ping-Ping Jiang4, Sönke Detlefsen5, Steffen Husby6 & Mathias Rathe6,7,*

Mucositis is a serious adverse effect of chemotherapeutic treatment. During intestinal mucositis, the mucosal barrier is compromised, increasing the risk of severe infections. Mucositis necessitates dose reduction or pauses in treatment, which affect the outcome of the treatment. Deleted in malignant brain tumors 1 (DMBT1) is a secreted scavenger protein with effects on innate immunity and epithelial regeneration. We have previously shown that jejunal DMBT1 expression is increased in piglets during chemotherapeutic treatment. We hypothesized that DMBT1 ameliorates doxorubicin-induced mucositis. Individually-caged Dmbt1+/+ (WT) and Dmbt1−/− (KO) female mouse littermates received intraperitoneal injections of either doxorubicin or saline. They were euthanized after three (D3) or seven days (D7). Weight loss was monitored every day, and serum citrulline levels were measured at termination. Intestinal tissue was analyzed for the expression of DMBT1 and proinflammatory cytokines (IL-1β, IL-6, and TNF). Specimens from the small intestines and colon were scored for inflammation and epithelial and mucosal architecture changes. We detected no effect of DMBT1 on weight loss, serum citrulline levels, expression of proinflammatory cytokines, or histologic damage. We detected a significant increase in crypt depth in WT mice compared to that in KO mice on D3. In conclusion, DMBT1 does not affect doxorubicin-induced mucositis in mice.

Depleted in malignant brain tumors 1 (DMBT1), also known as salivary agglutinin (SAG), salivary scavenger and agglutinin (SALSA), glycoprotein 340 and hensin, is a secreted scavenger protein with functions in mucosal innate immunity and epithelial differentiation and regeneration12,13. DMBT1 binds to dextran sodium sulfate (DSS) and carrageenan but does not reduce cytotoxicity in vitro14, while variations in the DMBT1-encoding gene are related to Crohn’s disease15,16. DMBT1 has antimicrobial and antiviral properties and binds to the innate immunoproteins surfactant A and surfactant D17–20. Loss of DMBT1 is associated with an increased risk of colorectal, thyroid, breast, and skin cancer21–24. DMBT1 promotes activation of the lectin pathway when bound to the cell surface and inhibits the lectin pathway when it is in solution25. We have previously shown that DMBT1 expression is upregulated during chemotherapy-induced mucositis in piglets26.
We hypothesized that DMBT1 might confer protective effects during chemotherapy-induced mucositis. We tested this hypothesis in a murine model of doxorubicin-induced mucositis by comparing WT mice expressing DMBT1 (\textit{Dmbt1}\textsuperscript{+\textasciitilde+}) with DMBT1-deficient KO mice (\textit{Dmbt1}\textsuperscript{-\textasciitilde/-}).

**Results**

Doxorubicin induces weight loss and decreases citrulline levels but does not affect intestinal length. Treatment with doxorubicin induced significant weight loss from day 0 to day 2 (WT NaCl vs WT Doxo \(p = 0.0013\); KO NaCl vs KO Doxo \(p = 0.0146\)), which was followed by a period of stagnation/minor restitution that showed the same course in mice with different genotypes (Fig. 1A). Doxorubicin treatment induced a significant decrease in citrulline levels on D3 but not on D7 compared to saline injection (Fig. 1B. WT NaCl vs WT Doxo D3 \(p = 0.0282\); KO NaCl vs KO Doxo D3 \(p = 0.0419\)). Since citrulline is a marker of functional enterocyte mass and absorption and gastrointestinal mucositis, these data indicate that the mice were still suffering from the effects of doxorubicin on D3 but were in the restitution phase on D7\textsuperscript{27,28}. We detected no significant effect of doxorubicin on the length of the small intestines and colon (Fig. 1C, D).

**Induction of DMBT1 expression in the jejunum and colon following doxorubicin treatment.** There was no significant difference in jejunal DMBT1 expression between WT and KO mice before doxorubicin treatment. However, following doxorubicin treatment, we observed an increase in the induction of DMBT1 expression in WT mice compared to that in KO (Fig. 2A. WT Doxo D3 vs KO Doxo D3 \(p = 0.0003\); WT Doxo D7 vs KO Doxo D7 \(p = 0.0058\)). In the colon, there was a significant difference in DMBT1 expression between WT and KO mice, which increased on D3 and D7 following doxorubicin treatment (Fig. 2B. WT NaCl vs KO NaCl \(p = 0.0257\); WT Doxo D3 vs KO Doxo D3 \(p = 0.0005\); WT Doxo D7 vs KO Doxo D7 \(p < 0.0001\)). The quantitative real-time polymerase chain reaction (qRT-PCR) cycle threshold (Ct) had a mean value of 27.9 for the jejunum and 20.2 for the colon in saline-treated WT mice.
This induction was also reflected on the protein level where the epithelial cells showed stronger staining for DMBT1 on D3 following treatment with doxorubicin in both colon and jejunum (Fig. 3). We also detected some DMBT1-staining of the Paneth cells in the jejunal crypts of KO mice (Fig. 3F).

**Induction of interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF) expression following doxorubicin treatment.** The proinflammatory cytokines IL-1β, IL-6, and TNF were measured by qRT-PCR analysis. We detected a significant increase in jejunal IL-6 expression in doxorubicin-treated WT and KO mice at D7 compared to that in saline-treated littermates (Fig. 4B. WT NaCl vs WT Doxo D7 $p = 0.0042$; KO NaCl vs KO Doxo D7 $p = 0.0424$), but there were no genotype-specific differences (Fig. 4).

**Doxorubicin-induced histologic damage in the jejunum but not in the colon.** Histologic damage was evaluated by examining hematoxylin and eosin (H&E)-stained colonic and small intestinal tissue. We detected no significant difference in the histologic damage score in the colonic tissue of mice subjected to saline and doxorubicin treatment (Fig. 5A). We detected no differences in histologic damage in the duodenum (Fig. 5B). In the jejunum, we detected a significant difference between the results of saline and doxorubicin treatment, as both WT and KO doxorubicin-treated mice showed increased histologic damage scores on D3 compared to mice treated with saline. There was no genotypic difference (Fig. 5C. WT NaCl vs WT Doxo D3 $p = 0.0001$; KO NaCl vs KO Doxo D3 $p = 0.001$). In the ileum there was only a significant difference between saline and doxorubicin in the WT group (Fig. 5D. WT NaCl vs WT Doxo D3 $p = 0.0017$). On D7, there were no
significant differences between the mice subjected to doxorubicin and saline treatments. Figure 6 show photo microscopy of H&E stained colonic and jejunal tissue.

**DMBT1 increased the duodenal crypt depth on D3.** Villus height and crypt depth were measured in H&E-stained tissue from the duodenum, jejunum, and ileum (Fig. 7). There was no difference in duodenal villus height between any of the groups (Fig. 7A), but we observed a significant increase in the duodenal crypt depth in doxorubicin-treated WT mice compared to that in doxorubicin-treated KO mice on D3 (Fig. 7B. WT Doxo D3 vs KO Doxo D3 p = 0.0377). In addition, we observed a significant increase in the crypt depth (Fig. 7B. KO NaCl vs KO Doxo D7 p = 0.0378) and an increase in the jejunal crypt depth in doxorubicin-treated KO mice compared with that in saline-treated KO mice on D7 (Fig. 7D. WT NaCl vs WT Doxo D7 p = 0.0009; KO NaCl vs KO Doxo D7 p = 0.0422). There were no differences in the villus height in the duodenum (Fig. 7A), jejunum (Fig. 7C), or ileum (Fig. 7E), or in crypt depth in the ileum (Fig. 7F).

**Discussion**

In the present in vivo study, we investigated the potential ameliorating effects of DMBT1 on chemotherapy-induced intestinal mucositis. Since a previous study detected increased intestinal DMBT1 expression in chemotherapy-treated piglets, and DMBT1 was shown to function in the immune system and in epithelial regeneration, we hypothesized that it would ameliorate chemotherapy-induced mucositis. However, we detected no significant effects of DMBT1 on weight loss, serum citrulline levels, intestinal length, expression of proinflammatory cytokines, or villus height.

Gastrointestinal mucositis may manifest as abdominal pains as well as diarrhea or constipation, nausea, and vomiting. Such clinical manifestations may vary between different cytotoxic regimens.

In the current study, Doxorubicin treatment resulted a significant decrease in citrulline levels on D3, weight loss and a significant difference between the results of saline and doxorubicin treatment, as both WT and KO doxorubicin-treated mice showed increased histologic damage scores on D3 compared to mice treated with saline. All hallmarks of GI toxicity. The decreased citrulline observed at day 3 as compared to saline treated
animals substantiates a relevant toxic effect on the GI mucosa. Based on these findings we conclude that doxorubicin-treated mice are relevant for studying chemotherapy-induced gut toxicity.

We observed a significant effect of DMBT1 on duodenal crypt depth on D3, where WT mice showed an increase in the crypt depth compared to KO mice following treatment with doxorubicin. However, since this was the only genotypic difference observed in this study and DMBT1 did not affect weight loss or serum citrulline levels, the clinical significance is limited.

Although we detected a significant increase in IL-6 expression on D7 in doxorubicin-treated animals, we detected no difference in the expression of IL-1β and TNF between mice given doxorubicin or saline treatment on D3 and D7. This could suggest that inflammation was already in resolution on D3. This is in line with the histologic evaluation of H&E-stained tissue, which showed the significant effect of doxorubicin in the small intestines on D3 but not on D7, and this highlights that gastrointestinal toxicity is a highly dynamic process.

We detected no difference in jejunal DMBT1 expression between saline WT and KO animals, suggesting the limited expression of DMBT1 in the WT animals. However, following chemotherapeutic treatment, there was a significant difference in the induction of DMBT1 expression in WT and KO mice on both D3 and D7 and a trend towards an increase in the expression of DMBT1 in WT mice. This is in line with previous observations showing that the expression of DMBT1 was upregulated in piglets during treatment with either busulfan plus cyclophosphamide or doxorubicin. We also detected an increased staining of DMBT1 in intestinal epithelial cells following treatment with doxorubicin in both colon and jejunum. We also detected some minor staining of jejunal crypts in KO mice, which could suggest that the KO mice were able to express DMBT1 in a minor degree. However, the expression of DMBT1 in jejunal tissue in the KO mice was very low and there was no increase of DMBT1 expression following treatment with doxorubicin. We therefore believe that the DMBT1-staining is more likely to be due to unspecific staining or at least of minor relevance.

A recent study investigating the distribution and localization of DMBT1 in healthy human tissue found that the DMBT1 cycle threshold (Ct) values in the jejunum and colon were 17 and 22, respectively. In comparison,
the Ct values for saline-treated mice were 28 and 20 for the jejunum and colon, respectively. The higher expression of DMBT1 in the human intestine compared with that in the murine intestine could indicate that DMBT1 is more likely to exert anti-inflammatory effects in humans. The increase in DMBT1 expression in the murine colon compared to that in the jejunum could indicate that DMBT1 mainly exerts its functions in the murine colon, whereas doxorubicin mainly induces inflammatory changes in the small intestines. A previous study found that DMBT1 WT mice were partially protected against DSS-induced colitis14, which also suggests that DMBT1 is more likely to exert its functions in the murine colon.

Previous studies examining the role of DMBT1 in mice found that deletion of hensin/DMBT1 was lethal on embryonic day 4.537 and that the conditional deletion of hensin/DMBT1 in intercalated cells resulted in distal renal tubular acidosis38, whereas the Dmbt1 tm1KUMC knockout strain did not show any effect on DSS-induced colitis39. For this study, we used DMBT1 knockout mice generated by Renner et al.16 that did not have any spontaneous phenotype and that previously had been shown to exhibit increased susceptibility to DSS-induced colitis. It is a limitation of this study that we only examined one mouse strain. However, since hensin/DMBT1 deletion is lethal in the embryonic stage and the Dmbt1 tm1KUMC strain showed no increased susceptibility to DSS-induced colitis, we believe that the strain produced by Renner et al. was the most appropriate for this study.

**Conclusion**

We detected no significant effects of DMBT1 on chemotherapy-induced weight loss, inflammatory markers, functional enterocyte mass, or histologic inflammation three and seven days after doxorubicin treatment in mice. WT mice had significantly deeper crypts on D3 than DMBT1 KO mice. Doxorubicin induced a nonsignificant increase in jejunal and colonic DMBT1 expression.
Methods

The mice were terminated prematurely according to humane endpoints if the weight loss exceeded 20% or if they showed a significant degree of pain. A total of five mice were prematurely terminated and excluded from the subsequent analysis due to reaching humane endpoints. These were three doxorubicin treated WT mice were terminated prior to endpoint due to weight loss > 20% (one at day 4 and two at day 5 and), one doxorubicin treated KO mouse was found dead at day 7, and one saline treated KO mouse was excluded due to injection error resulting in a necrotic kidney.

Animals and genotyping procedure. DMBT1 C57BL/6 knockout (KO) mice generated by Renner et al.16 were kindly provided by Prof Jan Mollenhauer and bred in-house from heterozygous Dmbt1^+/− parental mice, and the offspring were cohoused in litters of mixed genotypes until one week before the start of the experiment.

Figure 6. H&E-stained tissue. (A) colon from WT NaCl. (B) colon from WT Doxo D3. (C) colon from WT Doxo D7. (D) colon from KO NaCl. (E) colon from KO Doxo D3. (F) colon from KO Doxo D7. (G) jejunum from WT NaCl. (H) jejunum from WT Doxo D3. (I) jejunum from WT Doxo D7. (J) jejunum from KO NaCl. (K) jejunum from KO Doxo D3. (L) jejunum from KO Doxo D7. Bars indicate 100 μm.
Genotyping was performed on tail-tip biopsies both before and after the start of the experiment. DNA from tail biopsies was isolated using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) according to the supplier's instructions.

Seven days before the experiments, the mice were transferred from group housing into individual filter-top cages, allowing for acclimation to the new environment. Cages contained woodchip bedding, nesting material, tunnel housing, and a wooden chew. Food and water were supplied ad libitum. The mice were housed at 21–24 °C in 55% humidity and a 12-h light/dark cycle.

Ten- to 12-week-old female wild-type (WT) and KO littermates were included in the experiment.

**Mucositis induction and collection of samples.** A total of 62 mice were randomized into eight treatment groups. Mucositis was induced with 20 mg/kg doxorubicin (Doxorubicin Accord, Accord Healthcare Lim-
that was diluted 1:1 in isotonic saline and administered by two bilateral intraperitoneal injections. The control mice were injected with an equivalent volume of isotonic saline.

The following mice were included in the subsequent analysis: 20 mice (10 WT and 10 KO) received doxorubicin and were terminated three days after the injection (D3); 10 mice (5 WT and 5 KO) received saline and were terminated on D3; 22 mice (12 WT and 10 KO) received doxorubicin and were terminated seven days after the injection (D7); and 10 mice (5 WT and 5 KO) received saline and were terminated on D7. In all subsequent figures, the results for the saline groups from D3 and D7 were pooled into WT and KO groups.

Terminations were carried out by cardiac puncture under ketamine/xylazine anesthesia (100 mg/kg/10 mg/kg (MSD Animal Health, Copenhagen, Denmark/Recipharm Monts, France)) followed by cervical dislocation. Blood was stored at room temperature for at least two hours and centrifuged (2000 x g, 10 min, 4 °C), and the serum was separated and frozen at –80 °C. After blood sampling, the heart was perfused with 10 mL of cold, sterile phosphate-buffered saline (PBS) (Sigma-Aldrich Chemie, Steinheim, Germany). The small intestine from the pyloric sphincter to the ileocecal transition was removed, measured, and cut into three equal-sized pieces representing the duodenal, jejunal, and ileal parts of the small intestine. The colon was also removed and measured. The distal ends of all segments were used for histological examination. The remaining segments were cut longitudinally, washed three times in 45 mL sterile PBS, snap-frozen in liquid nitrogen, and stored at –80 °C prior to further processing.

Citrulline measurement. Serum levels of citrulline were measured and quantified using a UPLC-TQD MS (Waters, Milford, MA, USA) as described previously41 by a blinded researcher.

Quantitative real-time PCR (qRT-PCR) of DMBT1, IL-1β, IL-6, and TNF. RNA was isolated from small intestinal and colonic tissue using Isol-RNA Lysis Reagent (5 Prime GmbH, Hamburg, Germany) according to the manufacturer’s instructions. RNA was analyzed using a NanoDrop (Thermo Scientific, Wilmington, DE, USA) to determine the concentration and purity. All RNA samples had an A260/A280 ratio > 1.8, suggesting adequate purity.

Complementary DNA (cDNA) was synthesized by an M-MLV Reverse Transcriptase kit (Sigma-Aldrich, Taufkirchen, Germany) according to the manufacturer’s instructions. RT-PCR analysis was performed using TaqMan Universal Master mix II with no UNG (Applied Biosystems, Foster City, CA, USA) and TaqMan Gene Expression Assays for DMBT1 (Mm00455996), IL-1β (Mm00434228), IL-6 (Mm00446190), and TNF (Mm00443258) (Applied Biosystems, Foster City, CA, USA).

A pilot study was conducted to establish the appropriate endogenous control, and glyceraldehyde 3-phosphate dehydrogenase (Gapdh, Mm99999915) was selected due to its high and consistent expression in different groups.

Reactions were performed in duplicate by a blinded researcher using a StepOnePlus real-time PCR system (Applied Biosystems, Foster City, CA, USA). mRNA expression was determined relative to that of Gapdh using the 2−ΔΔCt method and expressed as the fold change. qRT-PCR data were normalized to the data obtained from the WT Saline D3 or D7 group using the GeNorm method42.

Histological preparation and evaluation. The samples for histological analysis were fixed for 24 h in 4% formaldehyde in aqueous solution (VWR chemicals, Leuven, Belgium), transferred to PBS with 0.05% NaN₃ and stored at 4 °C until paraffin embedding and sectioning. The evaluation of tissue architecture and inflammatory activity was performed on H&E-stained tissue. The tissue was also stained for CD45 (Rat Anti-Mouse 30F11 antibody, BD Pharmingen, Albertslund, Denmark) and Ki67 (SP6, Rabbit Monoclonal Antibody, Cell Marque, Rocklin, California, USA) that was diluted 1:1 in isotonic saline and administered by two bilateral intraperitoneal injections. The control mice were injected with an equivalent volume of isotonic saline.

The degree of intestinal inflammation, tissue damage, villous atrophy, and crypt hyperplasia were assessed using scoring methods for the small intestine modified from Kaczmarek et al.43 and de Koning et al.44. Small intestinal tissue was scored from 0 to 4 based on inflammatory cell infiltration and intestinal architecture, with a higher score representing increased severity. Villus height was measured from the villus-crypt junction to the villus tip in villi from a single layer of epithelial cells cut through the nuclei around the villus. Crypt depth was measured from the base of the crypt to the villus-crypt junction in crypts with open lumens and a continuous cell column on each side. Villus height and crypt depth were measured by a blinded researcher.

Colonic tissue was evaluated according to the method described in Kim et al.45. Scores ranged from 0 to 5 based on inflammatory cell infiltration, epithelial changes, and mucosal architecture. A higher score represented more severe damage. Scoring was based on H&E-stained tissue and either CD45-stained slides (which aided in the evaluation of inflammation) or Ki67-stained slides (which aided in the evaluation of epithelial hyperplasia). All histological evaluations were performed by a blinded gastrointestinal pathologist.

Statistical analysis. The Kruskal–Wallis test with Dunn’s correction was used to analyze weight loss, the levels of citrulline, expression of DMBT1, expression of proinflammatory cytokines, and histologic damage score. One-way ANOVA with Sidak’s test was used to analyze the intestinal length, villus height and crypt depth. Normality was determined using the Shapiro Wilks’ test and visually inspected using Q–Q plots. The alpha level for all tests was 0.05. A p-value < 0.05 was considered significant. All data are presented as the mean ± standard error of the mean (SEM). All tests were performed with GraphPad Prism (version 8.3.1; GraphPad Software, La Jolla, CA).
Ethical statement. All procedures were approved by the Danish National Committee on Animal Experimentation (J.no. 2014-15-0201-00417). All methods and procedures were performed in accordance with guidelines and regulations approved by the Danish National Committee on Animal Experimentation. The manuscript was prepared per the ARRIVE guidelines.

Received: 30 June 2020; Accepted: 6 July 2021
Published online: 19 July 2021

References
1. Sonis, S. T. et al. Perspectives on cancer therapy-induced mucosal injury. Cancer 100, 1995–2025 (2004).
2. Kuiken, N. S. S., Rings, E. H. M. & Tissing, W. J. E. Risk analysis, diagnosis and management of gastrointestinal mucositis in pediatric cancer patients. Crit. Rev. Oncol. Hematol. 94, 87–97 (2015).
3. Keefe, D. M. K., Brealey, J., Goland, G. J. & Cummins, A. G. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 47, 632–637 (2000).
4. Di Fiore, F. & Van Cutsem, E. Acute and long-term gastrointestinal consequences of chemotherapy. Best Pract. Res. Clin. Gastroenterol. 23, 113–124 (2009).
5. Herbers, A. H. E., De Haan, A. F. J., Van der Velden, W. J. F. M., Donnelly, J. P. & Blilievens, N. M. A. Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients. Transpl. Infect. Dis. 16, 279–285 (2014).
6. Marin, M. et al. Bloodstream infections in neutropenic patients with cancer: Differences between patients with haematological malignancies and solid tumours. J. Infect. 69, 417–423 (2014).
7. Lalla, R. V. et al. MACC3/ISO2 clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120, 1453–1461 (2014).
8. Van Sebille, Y. Z. A. et al. Management of mucositis during chemotherapy: From pathopharmacology to pragmatic therapeutics. Curr. Oncol. Rep. 17, 50 (2015).
9. Villa, A. & Sonis, S. T. Pharmacotherapy for the management of cancer regimen-related oral mucositis. Exp. Opin. Pharmacother. 17, 1801–1807 (2016).
10. Basile, D. et al. Mucosal injury during anti-cancer treatment: From pathobiology to bedside. Cancers (Basel) 11, 1–22 (2019).
11. Bachour, P. C. & Sonis, S. T. Predicting mucositis risk associated with cytotoxic cancer treatment regimens: Rationale, complexity, and challenges. Curr. Opin. Support. Palliat. Care 12, 198–210 (2018).
12. Madsen, J., Mollenhauer, J. & Holmskov, U. Gp-340/DMBT1 in mucosal innate immunity. Innate Immun. 16, 160–167 (2010).
13. Reichhardt, M. P., Holmskov, U. & Meri, S. SALSA—A dance on a slippery floor with changing partners. Mol. Immunol. 89, 100–110 (2017).
14. End, C. et al. DMBT1 functions as pattern-recognition molecule for poly-sulfated and poly-phosphorylated ligands. Eur. J. Immunol. 39, 833–842 (2009).
15. Madsen, J. et al. A variant form of the human deleted in malignant brain tumor 1 (DMBT1) gene shows increased expression in inflammatory bowel diseases and interacts with dimeric trefoil factor 3 (TFF3). PLoS ONE 8, e64441 (2013).
16. Renner, M. et al. DMBT1 confers mucosal protection in vivo and a deletion variant is associated with Crohn’s disease. Gastroenterology 133, 1499–1509 (2007).
17. Holmskov, U. et al. Isolation and characterization of a new member of the scavenger receptor superfamily, glycoprotein-340 (gp-340), as a lung surfactant protein-D binding molecule. J. Biol. Chem. 272, 13743–13749 (1997).
18. Tino, M. J. & Wright, J. K. Glycoprotein-340 binds surfactant protein-a (SP-A) and stimulates alveolar macrophage migration in an SP-A-independent manner. Am. J. Respir. Cell Mol. Biol. 20, 759–768 (1999).
19. Li, J. et al. DMBT1 inhibition of Pseudomonas aeruginosa twitching motility involves its N-glycosylation and cannot be conferred by the scavenger receptor cysteine-rich bacteria-binding peptide domain. Sci. Rep. 9, 1–13 (2019).
20. Li, J., Metruccio, M. M. E., Smith, R. E., Evans, D. J. & Fleiszig, S. M. J. Mucosal fluid glycoprotein DMBT1 suppresses twitching motility and virulence of the opportunistic pathogen Pseudomonas aeruginosa. PLoS Pathog. 13, e1006612 (2017).
21. Park, H. S. et al. Deleted in malignant brain tumor 1 is a novel prognostic marker in colorectal cancer. Oncol. Rep. 39, 2279–2287 (2018).
22. Sun, Z. & Xu, L. Expression of PDK-1 and DMBT1 in the thyroid carcinoma and its clinicopathological significance. Oncol. Lett. 18, 2819–2824. https://doi.org/10.3892/ol.2019.10639 (2019).
23. Braidoti, P. et al. DMBT1 expression is down-regulated in breast cancer. BMC Cancer 4, 1–9 (2004).
24. Mollenhauer, J. et al. Frequent downregulation of DMBT1 and galec tin-3 in epithelial skin cancer. Int. J. Cancer 105, 149–157 (2003).
25. Reichhardt, M. P. et al. The salivary scavenger and agglutinin binds MBL and regulates the lectin pathway of complement in solution and on surfaces. Front. Immunol. 3, 205 (2012).
26. Rathie, M. et al. Chemotherapy modulates intestinal immune gene expression including surfactant Protein-D and deleted in malignant brain tumors 1 in piglets. Chemotherapy 61, 204–216 (2016).
27. Fragkos, K. C. & Forbes, A. Citrulline as a marker of intestinal function and absorption in clinical settings: A systematic review and meta-analysis. United Eur. Gastroenterol. J. 6, 181–191 (2018).
28. Barzal, J. A., Szczylik, C., Rzepczi, P., Jaworska, M. & Anusiewska, E. Plasma citrulline level as a biomarker for cancer therapy-induced small bowel mucosal damage. Acta Biochim. Pol. 61, 615–631 (2014).
29. Sonis, S. T. Regimen-related gastrointestinal toxicities in cancer patients. Curr. Opin. Support. Palliat. Care 4, 26–30 (2010).
30. Herbers, A. H., Feuth, T., Donnelly, J. P. & Blilievens, N. M. Citrulline-based assessment score: First choice for measuring and monitoring intestinal failure after high-dose chemotherapy. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 21, 1706–1711 (2010).
31. van Vliet, M. J. et al. Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients. Pediatr. Blood Cancer 53, 1188–1194 (2009).
32. Blilievens, N. M. A., Lutgens, L. C. H. W., Schattenberg, A. V. M. B. & Donnelly, J. P. Citrulline: A potentially simple quantitative determination bacteremia among hematopoietic stem cell transplant recipients. Bone Marrow Transpl. 34, 193–196 (2004).
33. Van Der Velden, W. J. F. M. et al. Citrulline and albumin as biomarkers for gastrointestinal mucositis in recipients of hematopoietic SCT. Bone Marrow Transpl. 48, 977–981 (2013).
34. Gosselin, K. B. et al. Serum citrulline as a biomarker of gastrointestinal function during hematopoietic cell transplantation in children. J. Pediatr. Gastroenterol. Nutr. 58, 709–714 (2014).
35. Bowen, J. M. et al. Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. Int. J. Cancer 121, 1847–1856 (2007).
36. Bathum Nexoe, A. et al. Immunohistochemical localization of deleted in malignant brain tumors 1 in normal human tissues. J. Histoch. Cytoch. 68, 377–387 (2020).
37. Takito, J. & Al-Awqati, Q. Conversion of ES cells to columnar epithelia by hensin and to squamous epithelia by laminin. J. Cell Biol. 166, 1093–1102 (2004).
38. Gao, X. B. et al. Deletion of hensin/DMBT1 blocks conversion of β- to α-intercalated cells and induces distal renal tubular acidosis. Proc. Natl. Acad. Sci. USA 107, 21872–21877 (2010).

39. De Lisle, R. C., Xu, W., Roe, B. A. & Ziemer, D. Effects of muclin (Dmbt1) deficiency on the gastrointestinal system. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G717–G727 (2008).

40. Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: The arrive guidelines for reporting animal research. PLoS Biol. 8, 1–2 (2010).

41. Demacker, P. N. M. et al. Plasma citrulline measurement using UPLC tandem mass-spectrometry to determine small intestinal enterocyte pathology. J. Chromatogr. B 877, 387–392 (2009).

42. Vandesompele, J. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, 34–41 (2002).

43. Kaczmarek, A., Brinkman, B. M., Heyndrickx, L., Vandenabeele, P. & Krysko, D. V. Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways. J. Pathol. 226, 598–608 (2012).

44. de Koning, B. A. E. et al. Contributions of mucosal immune cells to methotrexate-induced mucositis. Int. Immunol. 18, 941–949 (2006).

45. Kim, J. J., Shajib, M. S., Manocha, M. M. & Khan, W. I. Investigating intestinal inflammation in DSS-induced model of IBD. J. Vis. Exp. https://doi.org/10.3791/3678 (2012).

Acknowledgements
We gratefully thank M.Sc. Kimmie B. Colmorten, University of Southern Denmark, Department of Cancer and Inflammation Research, for proofreading of the manuscript and valuable input and criticism, and Maria Fuglsang Bruun, Department of Pathology, Odense University Hospital, for aiding in the scoring of histological damage. This study was supported by grants from the Odense University Hospital Free Research Fund, The Danish Cancer Society, the Danish Child Cancer Foundation, and Overlægerådets Forskningsfond.

Author contributions
U.H., S.H. and M.R. conceptualized the study. A.A.P. and A.B.N. performed the in vivo experiment. A.A.P. and Sv.H. performed the qRT-PCR analysis. A.B.N. and S.D. evaluated the H&E-stained small intestinal and colonic tissue. S.D. evaluated the CD45- and Ki67-stained small intestinal and colonic tissue. P.J. performed the serum citrulline measurements. A.B.N. drafted the manuscript and assembled all figures. All authors have read and approved the final manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to M.R.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021